TMCnet News
Prostate Cancer Heat Map and Pipeline Analysis 2016-2022 - Research and MarketsResearch and Markets has announced the addition of the "Prostate Cancer - Heat Map and Analysis" report to their offering. The PC market consists of therapies for both hormone-sensitive and castration-resistant forms of the disease. The options available for the two forms are notably different, with hormonal therapies used in the hormone-sensitive stage, and chemotherapy or targeted therapies used in the castration-resistant stage. Castration-resistant PC relates to both symptomatic and asymptomatic forms of the disease that no longer respond to hormonal therapy. Hormonal therapies are widely used across multiple stages of hormone-sensitive disease, and the goal is to halt PC growth stimulated by testosterone. There are two methods used to treat PC through targeting hormones. The first is androgen deprivation therapy (ADT) using gonadotropin releasing hormone (GnRH) agonists and antagonists, and the second is androgen receptor (AR) blockage, using compounds termed anti-androgens. The differences between many of these products are relatively nuanced, and mut be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the PC market and late-stage pipeline. These are split along lines of therapy, and are therefore reflective of the treatment algorithm. All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use. The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline. Scope - What are the clinical characteristics of currently approved therapies for PC, in terms of specific safety and efficacy parameters? - What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are most closely linked to them? - Which novel classes of therapy are expected to emerge in the treatment of PC? - Which targets do these therapies act upon? - Which sub-types of patients could potentially benefit from these new products? Key Topics Covered: 1. Table of Contents 2. Introduction 3. Marketed Products 4. Pipeline Products 5. Appendix For more information about this report visit http://www.researchandmarkets.com/research/q532zs/prostate_cancer
View source version on businesswire.com: http://www.businesswire.com/news/home/20170116005319/en/ |
